Biosamples from the Framingham Heart Study will be used.

BG Medicine, the National Heart, Lung, and Blood Institute (NHLBI), and Boston University (BU) will jointly undertake biomarker discovery studies for heart disease and early detection of metabolic syndrome.

Under this CRADA, BG Medicine’s technology will be used to analyze biosamples obtained during years of collection by Framingham Heart Study researchers. The Framingham Heart Study is funded by NHLBI and conducted in collaboration with BU’s School of Medicine and School of Public Health.

Only information from participants who have consented to sharing their specimens and data with commercial researchers will be used, and all shared information will be de-identified to protect participants’ privacy.

Previous articleAvigen Implores Shareholders to Steer Clear of BVF’s Attempts to Gain Control of the Company
Next articleResearchers Discover Gene Variations that Protect against Cervical Cancer